A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Paolo Strati; Loretta J. Nastoupil; Richard E. Davis; Luis E. Fayad; Nathan Fowler; Fredrick B. Hagemeister; Larry Kwak; Yasuhiro Oki; Michael Wang; Jason Westin; Charnelle E. Ruben; Emily T. Wesson; Richard Piekarz; Michelle A. Fanale; Hun Ju Lee

doi:10.3324/haematol.2019.220012

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Paolo Strati, Loretta J. Nastoupil, Richard E. Davis, Luis E. Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry Kwak, Yasuhiro Oki, Michael Wang, Jason Westin, Charnelle E. Ruben, Emily T. Wesson, Richard Piekarz, Michelle A. Fanale, Hun Ju Lee

Lymphoma-Myeloma

Research output: Contribution to journal › Letter › peer-review

18 Scopus citations

Original language	English (US)
Pages (from-to)	E26-E28
Journal	Haematologica
Volume	105
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2019.220012
State	Published - 2020

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.3324/haematol.2019.220012

Cite this

Strati, P., Nastoupil, L. J., Davis, R. E., Fayad, L. E., Fowler, N., Hagemeister, F. B., Kwak, L., Oki, Y., Wang, M., Westin, J., Ruben, C. E., Wesson, E. T., Piekarz, R., Fanale, M. A., & Lee, H. J. (2020). A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica, 105(1), E26-E28. https://doi.org/10.3324/haematol.2019.220012

Strati, P , Nastoupil, LJ , Davis, RE , Fayad, LE, Fowler, N, Hagemeister, FB, Kwak, L, Oki, Y, Wang, M , Westin, J, Ruben, CE, Wesson, ET, Piekarz, R, Fanale, MA & Lee, HJ 2020, 'A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas', Haematologica, vol. 105, no. 1, pp. E26-E28. https://doi.org/10.3324/haematol.2019.220012

@article{fdd7ee570957416ca4411020bb58a737,

title = "A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas",

author = "Paolo Strati and Nastoupil, {Loretta J.} and Davis, {Richard E.} and Fayad, {Luis E.} and Nathan Fowler and Hagemeister, {Fredrick B.} and Larry Kwak and Yasuhiro Oki and Michael Wang and Jason Westin and Ruben, {Charnelle E.} and Wesson, {Emily T.} and Richard Piekarz and Fanale, {Michelle A.} and Lee, {Hun Ju}",

note = "Funding Information: 1Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX;2Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX and 3Investigational Drug Branch of CTEP, National Cancer Institute, Bethesda, MD, USA Funding: NCI-CTEP U01 Grant Program at MDACC, Celgene, Millennium/Takeda, and National Stem Cell Foundation. Correspondence: HUN JU LEE - hunlee@mdanderson.org doi:10.3324/haematol.2019.220012 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.",

year = "2020",

doi = "10.3324/haematol.2019.220012",

language = "English (US)",

volume = "105",

pages = "E26--E28",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

TY - JOUR

T1 - A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

AU - Strati, Paolo

AU - Nastoupil, Loretta J.

AU - Davis, Richard E.

AU - Fayad, Luis E.

AU - Fowler, Nathan

AU - Hagemeister, Fredrick B.

AU - Kwak, Larry

AU - Oki, Yasuhiro

AU - Wang, Michael

AU - Westin, Jason

AU - Ruben, Charnelle E.

AU - Wesson, Emily T.

AU - Piekarz, Richard

AU - Fanale, Michelle A.

AU - Lee, Hun Ju

N1 - Funding Information: 1Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX;2Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX and 3Investigational Drug Branch of CTEP, National Cancer Institute, Bethesda, MD, USA Funding: NCI-CTEP U01 Grant Program at MDACC, Celgene, Millennium/Takeda, and National Stem Cell Foundation. Correspondence: HUN JU LEE - hunlee@mdanderson.org doi:10.3324/haematol.2019.220012 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85077403279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077403279&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.220012

DO - 10.3324/haematol.2019.220012

M3 - Letter

C2 - 31073068

AN - SCOPUS:85077403279

SN - 0390-6078

VL - 105

SP - E26-E28

JO - Haematologica

JF - Haematologica

IS - 1

ER -

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this